Attached files

file filename
10-K - ANNUAL REPORT PERIOD ENDING JUNE 30, 2009 - Innovation Pharmaceuticals Inc.form10k.htm
EX-4.2 - Innovation Pharmaceuticals Inc.exh2_1.htm
EX-4.1 - Innovation Pharmaceuticals Inc.exh4_1.htm
EX-31.1 - SARBANES OXLEY EXCHANGE ACT RULES 13A-15(F) AND 15D-15(F)) - Innovation Pharmaceuticals Inc.exh31_1.htm
EX-31.2 - SARBANES OXLEY EXCHANGE ACT RULES 13A-15(F) AND 15D-15(F)) - Innovation Pharmaceuticals Inc.exh31_2.htm
EX-10.17 - CONTRACT AGREEMENT GIRINDUS AMERICA, INC. - Innovation Pharmaceuticals Inc.exh10_17.htm

 
 

 


 
EXHIBIT 32.1
 
 
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
 
 
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Cellceutix Corporation, a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that: 
 
 
The Report on Form 10-K for the year ended June 30, 2009 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company. 
 
 
A signed original of this written statement required by Section 906 has been provided to Cellceutix Corporation and will be retained by Cellceutix Corporation and furnished to the Securities and Exchange Commission or its staff upon request. 
 
 
Dated:  October 8, 2009 
 
George W. Evans
(Principal Executive Officer)
 
 
/s/ Leo Ehrlich
Leo Ehrlich
(Principal Financial Officer)